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1INTRODUCTION
Salivary gland tumours are not only uncommon tumours but also generate 
much interest due to the following reasons:
i) Complex Anatomy 
ii) Relative infrequency
iii) variable biological behaviour
“ The usual variant of salivary gland is a tumour in which the benign 
variant is less benign than the usual benign variant and the malignant vari-
ant is less malignant than the usual malignant tumour”
                 - Acherman L V et al.
iv) Ranks top of any organ in the number of different tumours that is capable 
of generating
v) in addition to the named major salivary glands there are hundreds of mi-
nor salivary glands dispersed throughout the upper aerodigestive tract.
vi) Requirement of more surgical expertise as important nerves and vessels 
traverse through or adjacent to them.
2AIM OF THE STUDY
1. To find out the various epidemiological parameters of salivary gland tu-
mours.
2. To analyse various risk factors.
3. To analyse the various modes of presentation of salivary gland tumours
4. To review the role of  FNAC in accurately diagnosing / ruling out the 
salivary gland tumours.
5. To assess the incidence of minor salivary gland tumours.
6. To record the unexpected  and rare varieties of salivary gland tumours.
7. To analyse the various treatment modalities and the post operative com-
plications with special emphasis on facial nerve palsy/paresis.
8. To review the literature on the subject.
9. To compare the current study with already published data.
3HISTORICAL PERSPECTIVES 
The following are some of the historical perspectives leading to our current 
understanding of salivary gland tumours:
1656 AD - Thomas Wharton Submandibular Salivary gland duct
1660  - Neils Stensen Identified Parotid duct in Sheep Head
1669 - Bartholinus Sublingual gland
1772 -  Kaltschmeid First clinical discription of parotid 
   tumours
1781  - Siebold Pioneer of Parotid Surgery
1802 - Betrandi First surgical approach to parotidectomy
1808 - Samuel White First successful removal of parotid  
   gland
1841 - Augusto Berard Classification of SG tumours
1892 - Codreanu First total conservative parotidectomy
1910-40 - Blair Sistrunk & Bailey Various methods of facial nerve 
   protection
1935 - Ahibom & Kirklin Radical parotidectomy
1948 - Taylor & Garcelon Superficial parotidectomy with
   conservation of facial nerve
1965 - Hobsley & DavidPatey Modern trends in conservative 
   surgery
 
4EMBRYOGENESIS
Parotid Gland
Early in the sixth week of development, the parotid duct appears as a solid 
outgrowth of the oral epithelium. It grows posteriorly, towards the ear investing 
the facial nerve with its branches. The solid cords subsequently become canal-
ized, and the cells at the tips of the branches differentiate into secretory acini.
Aberrant embryogenesis leading to congenital anomalies like congenital 
agenesis, accessary glandular tissues (pterygoid lobe and acessory lobe) are rare. 
Most common is accessory tissue (SOCIA PAROTIS) along the parotid duct, into 
which small ducts of the accessory tissue empty. (Anson & McVay et al)
Submandibular gland
A groove in the floor of the mouth becomes converted into a tunnel whose 
blind end proliferates to form the secreting acini. Its origin is almost certainly 
ectodermal.
ANATOMY
PAROTID GLAND
1.PAROTID REGION
The part of the face below and in front of the ear and below the zygomatic 
arch is the parotid region. 
The principal features are the parotid gland and the masseter muscle..
2. PAROTID GLAND
The parotid gland is predominantly a serous salivary gland, with only a few 
scattered mucous acini. It has an irregular shape because it fills in the gap between 
the mastoid process, ramus of the mandible and styloid process, spilling over in 
5variable degrees on to the muscles attached to these bones. 
It is best described as having upper and lower poles and three surfaces that 
are most logically called lateral, anterior and deep. It is surrounded by a tough 
capsule the parotid sheath, derived from the investing layer of deep cervical fas-
cia. Mumps, a virus infection of the gland, is painful because the gland swells 
within this tight fibrous envelope.
The UPPER POLE is a small concave surface that adheres to the cartilage of 
the external acoustic meatus and lies adjacent to the capsule of the temporoman-
dibular joint. 
The LOWER POLE is rounded, lying below and behind the angle of the 
mandible and indented by it and sternocleidomastoid, and overlapping the poste-
rior belly of digastric.
LATERAL AND ANTERIOR SURFACE
The lateral surface is subcutaneous and almost flat. The anterior surface 
(often called anteromedial) is U-shaped, clasping the ramus of the mandible 
with masseter on its outer surface and the medical pterygoid on its inner surface 
inferiorly. The stylomandibular ligament separates this surface from the medial 
pterygoid and from the posterior part of the submandibular gland. 
The outer edge of this surface meets the lateral surface over masseter to 
form the convex anterior border, deep to which emerge the parotid duct and the 
five (groups of)  branches of the facial nerve that fan out over the face. From the 
deeper part of this surface the terminal branches of the external carotid artery 
(superficial temporal and maxillary) leave the gland.
DEEP SURFACE
The deep surface (often called posteromieial) is the most irregular and 
6complicated. It is indented by the mastoid process and its attached muscles (ster-
nocleidomastoid laterally and the posterior belly of digastric medially), and lies 
against the styloid process with its three attached muscles (stylohyoid, styloglos-
sus and stylopharyngeus) and two ligaments (stylohyoid and stylomandibular).
 The external carotid artery enters the gland through the lower part of this 
surface, which joins the deep edge of the anteriof surface. If the gland is large 
this edge extends forwards in front of the styloid process to approach the superior 
constrictor of the pharynx. The styloid process separates the gland from the inter-
nal jugular vein and (deeper) the internal carotid artery. 
The temporozygomatic and cervicofacial branches of the facial nerve enter 
the gland between the styloid and mastoid processes. If the gland is retracted 
forwards from sternocleidomastoid and the acoustic meatus (as during parotidec-
tomy), a small arrow-like projection of the meatal cartilage conveniently points 
downwards towards the nerve.
FACIAL NERVE
Embedded within  the gland are the facial nerve, retromandibular vein and 
external carotid artery, in that order from superficial to deep. 
Although the facial nerve enters the deep surface it passes forwards to  be-
come the most superficial of the embedded structures, as approached from the 
superficial surface. Note that the branches of the nerve emerge from behind the 
anterior border, not from the lateral surface. The gland is often described as hav-
ing superficial and deep parts in relation to the nerve branches, as though during 
development the nerve had become enclosed in a sandwich of two layers of pa-
rotid tissue, but this is not a current concept.  
Immediately. deep to the plane of the nerve branches is the retromandibular 
vein, which can be a guide to the position of the nerves; follow the tributaries of 
7the external jugular vein upwards into the gland, and the nerves will be found im-
mediately superficial to the veins. 
The external carotid artery and its two terminal branches are the deepest of 
the large structures within the gland. 
Lymph nodes of the preauricular group may be within the gland substance 
as well as just inside the capsule, and the gland is penetrated by filaments of the 
auriculotemporal nerve which provide the secretomotor fibres.
PAROTID DUCT (STENSEN’S DUCT)
The parotid duct  5 cm long, passes forwards across the masseter and turns 
around its anterior border to pierce the buccinator. It lies in the line between the 
intertragic notch of the auricle and the midpoint of the philtrum and is palpable .
 The duct opens on the mucous membrane of the cheek opposite the second 
upper molar tooth; it pierces the buccinator further back and runs forwards be-
beath the mucous membrane to its orifice--the valvular flap of mucous membrane 
so produced prevents inflation  of the gland when intraoral pressure is raised.
Blood Supply
Branhes from the external carotid artery supply the gland. Venous return is 
to the retromandibular vein.
Lymph drainage
Lymph drains to the nodes within the parotid sheath and thence with the ex-
ternal arotid artery to nodes of the upper group of deep cervical nodes.
NERVE SUPPLY
Parasympathetic
Secretomotor fibres arise from cell bodies in the oticganglion and reach 
8the gland by ‘hitch-hiking’ along the auriculotemporal nerve. The preganglionic 
fibres arise from cell bodies in the inferior salivary nucleus in the medulla, and 
travel by way of the glossopharyngeal nerve, its tympanic branch, the tympanic 
plexus and the lesser petrosal nerve to the otic ganglion. 
Sympathetic
Sympathetic (vasoconstrictor) fibres reach the gland from the superior cervi-
cal ganglion by way of the plexus on the external carotid and middle meningeal 
arteries. 
Sensory
The gland itself receives sensory fibres from the suriculotemporal nerve, but 
the parotid fascia receives its sensory innervation from the great auricular nerve 
(C2).
SUBMANDIBULAR GLAND
The submandibular gland, mixed mucous and serous in man, consists of 
large superficial part and a small deep part which are continuous with one another 
round the free posterior margin of mylohyoid.
The superficial part fills some of the space between the mandible, mylohyoid 
and the investing layer of deep cervical fascia, and so has three surfaces which 
may be called lateral, inferior and medial. 
Lateral Surface
The lateral surface lies against the submandibular fossa of the mandible, 
overlapping the front of the medial pterygoid insertion and being deeply grooved 
posteriorly by the facial artery which hooks under the mandible to reach the face 
at the front of the masseter muscle. 
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The superficial surface is covered by skin, platysma and the investing fascia 
and is crossed by the facial vein and the cervical branh of the facial nerve, and 
also by the marginal mandibular branch of the facial nerve if unusually low. Sub-
mandibular tymph nodes lie not only in contact with the surface of the gland but 
also within its substane -- hence the need to remove the gland as well as nodes in 
the operation of radical neck dissection. 
Medial Surface
Most of the medial surface lies against mylohyoid and its vessels, but to-
wards the back it overlaps hyoglossus and lingyual nerve, submandibular gan-
glion, hypoglossal nerve and deep lingual vein.
The deep part of the gland extends forwards for a variable distance, some-
times only a few millimetres, between mylohyoid and hyoglossis, with the lingual 
nerve above it and the submandibular duct and hypoglossal nerve below it.
Submandibular Duct
The submandibular duct (Wharton’s) is 5 cm long,  and emerges from the 
superficial part of the gland near the posterior border of mylohyoid. It runs for-
wards first between mylohyoid and hyoglossus and then between the sublingual 
gland and geniohyoid, to open into the floor of the mouth beside the frenulum.
Blood Supply
From the facial artery, with veins draining into the facial vein.
Lymph drainage
To the submandibular nodes.
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Nerve Supply
Secretometer fibres to the gland have their cell nodies in the submandibular 
ganglion with a few in small ganglionic masses on the surface of the gland itself. 
The preganglionic fibres pass from cell bodies in the superior salivary nucleus 
in the pons by way of the nervus intermedius, chorda tympani and the lingual 
nerve.
 Sympathetic (vasoconstrictor) fibres come from the plexus around the facial 
artery.
SUBLINGUAL GLAND
The sublingual gland is almond-shaped and lies in front of the anterior bor-
der of hyoglossus, between mylohyoid below and in front and the side of the 
tongue (genioglossus) medially. 
Laterally it lies against the sublingual fossa of the mandible. Its upper surface 
raises the sublingual fold in the floor of the mouth. At the front the two glands al-
most meet each other; at the back each is separated from the submandibular gland 
by the stylomandibular ligament. The gland is mucus-secreting  and of its 15 or 
so ducts, half open directly into the submandibular duct, the remainder separately 
on the sublingual fold.
It is supplied by the lingual artery and by branches of the submental artery 
which pierce mylohyoid muscle to reach it. The venous return is by correspond-
ing veins. It is innervated from the submandibular ganglion.
MINOR SALIVARY GLAND
Located in the mucosa itself & present in the upper aero digestive tract, there 
are about 600 to 1000 glands distributed in 
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• Oral cavity
• Pharynx
• Nasal cavity & para nasal sinus
• Larynx
Highest density is present in the palete.
Batsaki’s has recorded choristomas in body of mandible lower part of neck 
hypopharynx, sternoclavicular joint and Ha et al has described a case of choris-
toma of middle ear.
HISTOLOGICAL FEATURES
Histological sections of the parotid gland are characterized by three features 
that distinguish it from the other main salivary glands: predominantly serous 
acini, many ducts, and fat cells scattered between the acini and ducts. 
Submandibular gland
The submandibular gland,  has a mixture of serous and mucous acini (in-
cluding mucous acini with serous demilunes at their periphery), and few ducts.
Sublingual gland
The sublingual gland which has almost exclusively mucous acini and few 
ducts.
12
PHYSIOLOGY
Total salivary discretion is 1.25  litres per day.
Glands Nature % of secretion
Parotid Serous 20%
Submandibular Mixed 70%
Sub lingual Mucous 5%
Minor Mixed 5%
Function of salivary glands
Salivary glands serve various functions like deglutition and speech through 
its moisturising action. It also improves taste sensation through its  solvent ac-
tion. It aids in digestion as it contains various digestive enzymes like amylase and 
lipase. It also has antimicrobial functions through its IgA and Lysozyme.
Neual Control of salivary secretion.
Salivary secretion is under neural control and is largely independent of 
hormonal control. Stimulation of parasympathetic supply causes vasodilation of 
gland followed profuse secretion of watery saliva and relatively low content of 
organic material.
Stimulation of sympathetic causes vasoconstriction and secretion of saliva 
rich in organic material.
Salivary secretion is stimulated by food in the mouth in the mouth sight, 
smell and thought of food.  There are two phases of secretion, one is resting phase 
and the other is gustatory phase.
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ETIOPATHOGENESIS
ETIOLOGY
Low dose irradiation (causes 9 times the risk of cancer as studies from Hi-
roshima shows) 
Smoking – Warthin’s  tumor
UV irradiation
EBV – Lymphoepithelial carcinoma
Silica exposure - For Parotid Carcinoma
Rubber workers exposed to nitrosamine
Early menarche & nulliparity 
Genetic factors - Allelic loss of chromosme 12q leading to pleomorphic 
adenoma
Diet – PUFA – Protective
But except for radiotherapy and smoking effects, others are not well proved 
beyond doubt.
PATHOGENESIS
WHO CLASSIFICATION
Adenomas 
Carcinomas
Non epithelial tumors
Malignant lymphomas
Secondary tumors
Unclassified tumors
Tumor like lesions
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EPITHELIAL TUMOURS
 ADENOMA     CARCINOMA
Myoepithelioma    LOW GRADE
Pleomorphic adenoma   Acinic cell carcinoma
Basal cell adenoma    Mucoepidermoid carcinoma
Warthins tumor    HIGH GRADE
Oncocytoma     Mucoepidermoid carcinoma
Canalicular adenoma   Adenoid cystic carcinoma
Sebaceous adenoma    Malignant pleomorphic adenoma
Ductal papilloma    Carcinoma Ex pleomorphic ade
Inverted ductal papilloma   Squamous Cell Carcinoma 
Intraductal pailloma   Adnocarcinoma
Sialdenoma papilliferum   Oncocytic carcinoma
Cystadenoma    Salivary duct crcinoma
Papillary cystadenoma
Mucinous cystadenoma
NON-EPITHELIAL TUMOURS
 BENIGN      MALIGNANT
Hemangioma     Rhabdomyosarcoma
Lipoma     Malignant schwannoma
Lymphangioma    Fibrosarcoma 
       MFH
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       Melanoma
       Anaplastic carcinoma
TUMOR LIKE LESIONS
oncocytosis
Necrotising sialometaplasia(salivary gland infarction)
Benign lymphoepithelial lesion
Salivary gland cysts
Chronic sclerosing sialadenitis of submandibular gland(KUTTNER’S TU-
MOR)
Cystic lymphoid hyperplasia in AIDS
Sialadenosis
          THEROIES OF PATHOGENESIS
TWO THEORIES 
Bicellular reserve cell theory
Multicellular theory
Multicellular theory
This theory states that Salivary gland tumours are derived from different cell 
types in the adult salivary gland units
Warthin tumors
Oncocytic tumors
Striated duct cells
Acinic cell tumors Acinar cells
Squamous and mucoepidermoid carcinoma Excretory duct cells
Mixed tumors Intercalated duct & myoepithelial cells
16
BICELLULAR OR RESERVE CELL THEORY
This theory states that tumours arise from one of these two stem cells from 
which mature salivary gland units arises. 
BENIGN TUMOURS
Mixed tumor – Pleomorphic adenoma
It is a benign epithelial derived tumour, where both epithelial and mesenchy-
mal differentiation are seen. It is the most common neoplasm of salivary gland 
origin. Parotid is the most common site. Other glands may also be involved.
It is usually solitary and  most commonly associated with Warthin’s tumor. 
Peak incidenceis in the 4th decade of life. Women > men; it is a slow growing, 
discrete, mobile, often multinodular, firm mass.
When recurrent , multiple nodes which are less mobile are seen often in the 
tail of parotid. They constitute about 10% parapharyngeal mass. They may also 
cause facial paralysis due to compression.
Gross pathology
• Irregular,round to ovoid mass – well defined borders
• Encapsulated – incomplete fibrous capsule
• Minor salivary – unencapsulated
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• Cut surface 
  Homogenous tan to white nodules connected by delicate fibrous  
  septa
Histopathology 
• Both epithelial & mesenchymal differentiation 
• Epithelial - Well formed ductal structures  - Squamous differentia 
  tion- keratin pearls
• Mesenchymal component
  Myxoid, hyaline, Cartilagenous / osseous
Epithelial element predominates > 80%
Myxoid type
Myxochondromatous mesenchymal element predominates
Thickness of the  fibrous capsule varies
MODERN TECHNIQUES
Special stains & immunohistochemistry
Myxochondroid areas Heparin sulfate
Myoepithelial cells Cytokeratin, smooth muscle actin (SMA) 
&  S-100 protien
Ductal epithelium Cytokeratin, epithelial membrane antigen 
(EMA), carcinoembryonic antigen(CEA)
Cytogenetic studies
Clonal chromosomal abnormalities, 8q12 and 12q13-15
Patients with 8q12 abnormalities are typically younger
No correlation with prognosis
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Metastasizing mixed tumor
It has entirely benign histologic appearance and the most common sites are 
BONE & LUNG, but also to regional lymph nodes; skin; kidney; retroperitoneum; 
oral region; pharynx; skull; brain; even abdominal scars(1 case). It can be viru-
lent
MYOEPITHELIOMA
Eventhough rare tumours, they are given special consideration, because of 
their occurence in our study.
It is a benign tumor composed of cells with myoepithelial differentiation and 
it is also considered as one end of spectrum of pleomorphic adenoma. Most com-
mon site is parotid involved in about  40% of cases,  the intraoral minor salivary 
glands are less common sites of occurence (21%).   Men=women. Peak incidence 
is 3rd decade. It presents as an asymptomatic mass.
Myoepithelioma is a rare benign neoplasm of salivary gland  composed of 
myoepithelial cells and first described in 1943. It accounts for less than 1% of all 
salivary gland tumors. 
Gross pathology
Well circumscribed
Often nodular
Well defined fibrous capsule
C/S solid, yellow tan and glistening
19
Histopathology
Three variants
Spindle cell (M.C)
Epitheloid cell
Plasmacytoid cell (hyaline cells)
Sometimes predominance of clear cells
Myoepithelioma clear cell type should be regarded as potentially malignant
Due to their infrequency and variety of histopathologic features, diagnosis 
of myoepithelioma is not easy by light microscopy alone. Immunocytochemistry 
can aid in diagnosis 
WARTHIN’S TUMOR
Papillary Cystadenoma Lymphamatosum
It is the 2nd most common benign parotid tumor and occurs in parotid ex-
clusively. It shows male predominance. Smoking is a proved etiology. It presents 
as a painless, sometimes fluctuant mass and is bilateral in  7%.    It presents with 
pain, facial nerve paralysis, ear ache and tinnitus.  It is usually multicentric, there-
fore requires wide surgical excision.
Gross pathology
Well circumscribed, ovoid nodule
Cut Section 
Clear, mucoid or brown fluid, or caseous debris
Irregular cystic spaces
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Small papillary excrescences
Intercystic areas may be hemorrhagic
Histopathology
Oncocytic epithelial component which form papillary projections into cystic 
lumina
Cystic spaces contain cast off epithelial cells , inflammatory cells , crystal-
line structures or corpora amylacea
Lymphoid stroma with well developed follicles
Modern techniques
Special stains & immunohistochemistry
Luminal cells – cytokeratin 
Lymphyoid stroma composed predominantly of mature B cells
B cells contain 50% IgG and 33% IGA
6p rearrangements and t(11;19) as being specific for warthin tumor
Scintigraphy
 The oncocytic cell concentrates sodium per-technate (99mTc) and shows a 
hot nodule
ONCOCYTOMA
Rare benign epithelial neoplasm- mitochondria rich ONCOCYTES
Predominant – parotid
Peak – 7th to 9th decades
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Marked female predominance in oncocytomas with clear cells
20% of pts – h/o radiation therapy to face / upper torso and are around 20 
years younger
Single, encapsulated, usually solid but cysts can occur
It consists Oncocytic cells which are large cells with intensely eosinophilic 
granular cytoplasm and a centrally located nucleus when clear cells are present 
called as clear cell oncocytoma.
MONOMORPHICADENOMA
There are two types: Canalicular & Basal cell
CANALICULAR ADENOMA
Exclusively in minor salivary glands
Most common in upper lip
Women>men
Canalicular adenoma
Cells are uniformally cuboidal or columnar
Arranged in cords of single cells that form parallel canals
Thin fibrous capsule
BASAL CELL ADENOMA
M.C – Parotid
Tend to occur in the superficial lobe and are freely movable
There are four types - Solid ( M.C), Trabecular, Tubular and Membranous
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SEBACEOUS NEOPLASMS
Sebaceous gland rests – submandibular , parotid , rare in lingual 
In buccal mucosa – FORDYCE’S GRANULES upto 80% of persons
Two benign tumors are there; Sebaceous adenoma and Sebaceous lymphad-
enoma
LIPOMA
It is a well encapsulated tumor, soft yellow in colour. Peak age incidence is 
5th to 6th decades. Surgical removal is easy. Associated with diabetes, cirrhosis, 
chronic alcoholism, malnutrition & hormonal disturbances
HEMANGIOMA
Eventhough they are rare, special consideration is given because of their oc-
currence in our study. It is most common in newborns and infants; Girls>boys. It 
usually involves the superficial lobe of parotid. 
It is a soft, fluid filled spongy tumour
Two types : capillary & cavernous
Usually of cavernous type
Can extend into hypopharynx & intracranially
CAPILLARY HAEMANGIOMA
Rare in parotid 
 More common in girls
 Manifests in infants  
 Unilateral and compressible 
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 Rapid enlargement & bluish discolouration of skin
 Spontaneous regression
CAVERNOUS HAEMANGIOMA
Occurs in older children or early adults
Presents as solitary or diffuse soft swelling 
Rapid increase in size with pain occur
TURKEY WATTLE SIGN  
Masseteric hypertrophy and trismus can occur.
It is rarely pulsatile ,Facial N Palsy can also be a manifestation.
TREATMENT
Treatment of choice is total parotidectomy.
MALIGNANT TUMOURS
MUCOEPIDERMOID CARCINOMA
It is the most common malignant tumour  80-90% of the tumours occur in 
the parotids; hard palate is the most common site of minor gland involvement and 
is common next to adenoid cystic carcinoma in minor salivary glands. Males and 
females affected with equal frequency; peak age range 4th decade.
HISTOPATHOLOGY
Gross
They are well circumscribed but there is little or no capsule. They are often 
infiltrative at the margins. 
24
Cutsection
Pale grey white revealing small musing containing cysts.
Histology
The basic pattern is that of  cords, sheets or cystic configurations. 
There are two cellular components – mucin-producing cells, epithelial epi-
dermoid cells. More the proportion of mucin-producing cells, lower the grade and 
better the prognosis. And the grade of the tumour has influence on the prognosis 
and metastasis. 
They may widely infiltrate the normal gland or may become fixed to the 
skin.
ADENOID CYSTIC CARCINOMA
It is the second-most common malignancy.  2% of parotid tumours and 
15% of submand. gland tumours and is the most common malignancy of minor 
salivary gland tumours i.e., upto 30% of minor salivary gland tumours.  Max. in-
cidence is in the 6th decade. Commonest clinical feature is facial pain. Perineural 
spread is characteristic which accounts for large number of pre-op facial paralysis 
and is also an important route for skull-base and intracranial spread.
Hematogenous mets cause pulmonary mets and local spread leads to man-
dibular involvement.  It varies in growth rate from slow to fast. Recurrence may 
occur many years after initial treatment.
HISTOPATHOLOGY
Gross 
Small, poorly encapsulated, infiltrative grey pink lesions.
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Histology
There are three types; 
i) Cribriform (Swiss cheese) type, 
ii) Solid type, and;
iii) tubular type.
The spaces between the tumour cells are often filled with a hyaline material 
thought to represent excess basement membrane.
MALIGNANT MIXED PAROTID TUMOUR
This has been used synonymously with carcinoma ex pleomorphic adenoma 
(carcinoma arising from a mixed tumour). The true malignant pleomorphic ad-
enoma is very rare and presents in two forms: the first is the benign pleomorphic 
adenoma which inexplicably metastasizes and the second is the carcinoma which 
develops after a number of years in a previously benign tumour. The carcinoma 
arising in a mixed cell tumour is commoner and represents 1-6% of mixed cell 
lesions. It is commonest in the parotid gland, then the submandibular gland 
followed by the monor salivary glands of the palate, lip, paranasal sinuses, na-
sopharynx and tonsil. The original mass will usually have been present for 5-15 
years and even when malignancy supervenes the tumour may remain grossly en-
capsulated. It has the worst prognosis of any salivary gland malignancy. There is 
an accelerated recurrence rate and a high incidence of metastases (30-70%). Most 
series report a 5 year survival rate of less than 40%.
ACINIC CELL CARCINOMA
This accounts for between 2% and 4% of all parotid gland tumours and like 
Warthin’s tumour it may be bilateral (3%). It is rarely found outside the parotid 
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gland. The peak age incidence is the fifth decade.
These tumours are derived from two cell sources: the reserve cells of the 
terminal tubules, or the intercalated ducts. They may also occur in intraparotid 
lymph nodes, a feature shared with Warthin’s tumour. They exhibit variable bio-
logical behaviour but survival rates of around 90% at 5 years make acinic cell car-
cinoma a much more benign tumour than mucoepidermoid carcinoma.Attempts 
to predict biological behaviour from histomorphological findings have not been 
fruitful. About 10% metastasize.
HISTOPATHOLOGY
There are two variants;
i) Classic variant, resembling normal serous salivary cells, and;
ii) clear cell variant.
The cells are disposed in sheets or microcystic, glandular, follicular or papil-
lary patterns. There is usually little or no anaplasia and few mitoses.
SQUAMOUS CELL CARCINOMA
This is a rare tumour in the salivary glands and almost never occurs in the 
minor glands. Two-thirds of patients are men and the maximum age incidence is 
in the seventh decde. It is an aggressive tumour and shows no tendency to encap-
sulation. It grows rapidly causing pain, skin fixation, ulceration and facial paraly-
sis when the parotid gland is involved. About one-half of patients have metastatic 
lymph glands when first seen. It appears to arise from the duct system and some 
pathologists deny its existence considering such tumours to be high-grade 
mucoepidermoid carcinomas. A possible source of diagnostic error in this situ-
ation is the tumour arising in a parotid lymph node as metastatic from another 
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head and neck site.
HISTOPATHOLOGY
MALIGNANT LYMPHO EPITHELIOMA -  PAROTID
It is a very rare tumor (< 0.4% of all salivary tumours). Total no. of cases 
reported in major & minor salivary glands is less than  150. ( Abdulla .ak et al., 
HEAD&NECK JOURNAL  2000 nov-  dec). It is common in eskimos & asians.
It is discussed as 1 case of malignant sympho epithelioma is reported in our 
study. EBV. (lezzoni et al.,1995) is considered as an aetiological agent. It has wide 
age range, with female predominance and is common in parotid,sub mandibular-
infrequent. It may arise from a benign lymphoepithelial lesion but majority arise 
de novo. Presents as painful mass.
 It shows frequent involvement of  facial n.& cervical L.N.
 
HISTOPATHOLOGY
It shows epithelial islands or nests.
1. Epithelial component
2. lymphoid component
Nasopharyngeal lymphoepithelioma- similar histology.    
IMMUNOHISTOCHEMISTRY;
  Cytokeratin; Epithelial cells are +ve
  Leucocyte common antigen : Highlights lymphoid component.
MODERN TECHNIQUES IN DIAGNOSIS; 
         
Detection – EBV genomes in malignant cells by in-situ hybridization.   
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DIFFERENTIAL DIAGNOSIS
Metastatic amelanotic melanoma.
Large cell lymphoma.
Benign lymphoepithelial lesion.
Metastatic nasopharyngeal lymphoepithelial carcinoma
TREATMENT
Complete surgical excision  with neck dissection followed by post operative 
radiotherapy.
Differential Diagnosis For Parotid Tumours
Hypertrophy of masseter muscle
Winged mandible )First arch syndrome)
Neuroma of facial nerve
Preauricular node
Sebaceous cysts
Enlarged Styloid process
Ptosis of the parotid gland (chrome alcoholic)
DEEP LOBE TUMOUR OF THE PAROTID
10% of tumours occur in the deep lobe
It displaces soft palate / tonsils medially
Differential Diagnosis for deep lobe tumours
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Minor salivary gland tumours
Parapharyngeal tumours
Aneurysm of ICA
Soft tissue sarcoma
Lesions of the tonsils
CLINICAL FEATURES
They usually present as painless slow-growing tumours.
Sudden increase in size may be due to ;
i)    Cystic degeneration
ii)   Intralesional haemorrhage
iii)  Malignant transformation
Previously painless mass may become tender
Pain may be due to local ulceration, nerve and other soft tissue infilteration 
or may be referred pain.
Difficulty in swallowing, hoarseness, change of voice seen in parapharyn-
geal tumours.
Neck lumps due to cervical node metastasis
Malignant tumours especially adenoid cystic carcinoma presents with facial 
nerve palsy. Facial nerve palsy can also occur in other high grade malignant tu-
mours, and in mixed parotid tumours due to compression.
Pain, numbness over the tongue in case of  submandibular gland tumours.
Clinical features of malignant salivary tumours include;
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i) facial nerve weakness;
ii) rapid enlargement of swelling;
iii) induration and/or ulceration of overlying skin; and
iv) cervical node enlargement
Minor salivary gland tumours 
Most of them are carcinomas. They present as a painless submucosal mass 
initially, later ulceration develops. Perineural involvement is expressed as pain or 
paresthesia. Lymph node metastasis occurs as predictable sites. Important differ-
ential diagnosis, is squamous cell carcinoma for the given site.
INVESTIGATIONS                         
FNAC/FNAB
FNAC is defined by Bamforth (1966) et al as “The examination of cells ob-
tained by needle or drill biopsy  in solid organs or tissue masses or from the cut 
surface of such material freshly removed by surgical biopsy”.
Fine Needle Aspiration Cytology or Biopsy is the commonest investigation 
performed for all the tumours. The first series of reports by Dr Martin & Ellis 
regarding this technique comes from Memorial Hospital for Cancer and allied 
Diseases, USA. First FNAC studies for  Parotid gland tumours comes from En-
eroth et al (1967).
The Advantages of FNAC are:
 Non-expensive
 Reliable and repeatable
Virtually no complications
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Easy technique
Can be performed as OP procedure
Not only for diagnosis, but also for follow-up
Complication rates are very dismal.
Requisites:
Good technique of procedure
Experienced cytopathologist
Adequate Clinical Information
Technique
Tumour is grasped with one hand and fixed.
21/23G needle with syringe inserted into the tumour mass and negative pres-
sure created
Multiple passes are made back and forth in slightly various directions main-
taining the negative pressure.
Now the negative pressure is withdrawn, needle with syringe is taken out
Negative pressure is again created and is transferred to the slide for air dried 
giemsa staining and wet fixation with E & H or papanicaolou stains.
Various studies have confirmed an accuracy rate of 86 to 92%, sensitivity of 
64 to 87% and specificity of 95 to 97%.
Useful for both neoplastic and non-neoplastic conditions.
Risk of seedling in case of malignant neoplasms is very negligble. But how-
ever it should be included  insubsequent excision. 
For deeplobe tumours image-guided FNAC is a well accepted and success
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INCISIONAL BIOPSY
Not routinely indicated. 
Risk of seedling and shedding high.
Indications
i) Skin involvement with undoubted features of carcinoma;
ii) For inoperable FNAC inconclusive tumours for pathologic confirmation 
and paliative treatment
iii) Minor salivary gland tumours
OTHER INVESTIGATIONS
ULTRASONOGRAPHY
New Technologies, including high-resolution probes and harmonic imaging, 
can delineate location, homogeneity or heterogeneity, shape, vascularity and mar-
gins of salivary tumors in the periauricular, buccal and submandibular area.
Ultrasonography may be able to reveal the type of tumor.
Ultrasonography can guide fine-needle aspiration to increase the likelihood 
of getting a good sample, and it can precisely guide core needle biopsies 97% of 
the time in an outpatient setting, which lessens the need for intraoperative biop-
sies.
CT/MRI
Indications
Large tumour of the parotid
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Deep lobe parotid tumours
Parapharyngeal tumours 
Malignant tumours
Minor salivary gland tumours
Most submandibular gland tumours
Features
Location and extent of the tumour
Nodal Involvement
Relation to major neurovascular structures
Perineural spread
Skullbase invasion
Intracranial extension
Features of malignancy
Irregular margins
Extraglandular extension
Bony destruction of the       mandible/skullbase
Bone marrow involvement
Neck nodes
Perineural spread
Sublingual and minor salivary gland
Tumours
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Parapharyngeal tumours
Deep lobe tumours are connected to the parotid gland in atleast one imaging 
section
Minor salivary gland tumours are completely surrounded by fatful method 
of diagnosis. 
POSITRON EMISSION TOMOGRAPHY
MERITS:
Detects tumour recurrence
Distinguish tumour from post treatment fibrosis
Measures tumour metabolisim 
DEMERITS:
Inconsistent uptake of FDG
Anatomic details can’t be obtained
High cost
At present it is now of research purposes only.
SIALOGRAPHY
Not useful in differentiating tumours
Can differentiate tumors from sialectasis
3D - sialography
Acinar structures visualised in detail
Entire parotid system shown in one image
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Contrast between bone and parotid possible
Surface structures of parotid easily understood
SULPHUR COLLOID SCAN
It shows hot spots in Warthin’s tumour and Oncocytoma. Others as cold 
spot
GALLIUM  SCAN
It shows diagnostic spots in lymphoepithelioma and inflamatory condi-
tions.  
FLOW CYTOMETRY
The value of flow cytometry in salivary gland neoplasms is supporting his-
topathology by detecting possibly malignant tumors.
Flow cytometry has also been shown to help in prognosis in adenoid cystic 
carcinoma by determining the DNA ploidy of tumor cels. This information has-
been shown to correlate with overall prognosis and long-term disease-free sur-
vival periods.
TNM STAGING – SALIVARY GLANDS
T 1    < =2 CM, WITHOUT EXTRAPAREN. EXTENSION
 T 2    > 2 – 4 CM, WITHOUT EXTRAPAREN. EXTENSION
 T 3   EXTRAPAREN. EXTENSION, & / OR > 4 –6 CM
 T 4   BASE OF SKULL, 7TH NERVE, &  / OR > 6 CM
 N 1   IPSILATERAL SINGLE , < = 3 CM
 N 2    IPSILATERAL SINGLE > 3 - 6 CM
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  IPSILATERAL MULTIPLE < = 6 CM
 BILATERAL, CONTRALATERAL < = 6 CM
 N 3    > 6 CM
M0 - No distant mets
M1 - Distant metastasis present.
STAGE GROUPING
STAGE I T1,2 N0               M0
STAGE II        T3 N0               M0
STAGE III       T1,2 N1               M0 
STAGE IV       T4 N0               M0
                         T3,4 N1               M0
                         ANY T N2               M0
                         ANY T N3               M0
                         ANY T ANY N        M1 
PROGNOSTIC INDICATORS FOR PAROTID CA
1) Grade of the tumour
2) Lymph node Metastasis
3) VII Nerve Palsy
4) Type of gland Non-parotid involvment
5) Staging III & IV
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6) Positive Surgical Margins
7) Perinevral Spread
FIVE YEAR STUDY RESULTS (FRAZELL)
MEC - Low grade - 96%
Acinic Cell Carcinoma - 82%
Malignang Mixed tumour - 55%
Solid adeno Carcinoma -  48%
Adenoid Cystic Carcinoma - 40%
Squamous Cell Carcinoma - 36%
Undiff Carcinoma - 24%
MEC - High grade - 14%
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TREATMENT
There are 3 methods of Treatment:
1) SURGERY
2) RADIOTHERAPY
3) CHEMOTHERAPY
SURGERY
Surgery for Parotid Gland : SUPERFICIAL CONSERVATIVE
  PAROTIDECTOMY
  TOTAL CONSERVATIVE 
  PAROTIDECTOMY
  RADICAL PAROTIDECTOMY
  ROLE OF NECK DISSECTION
Surgery for SM Gland : SUBMANDIBULAR GLAND
  EXCISION
  SUBMANDIBULAR TRIANGLE 
  DISSECTION
Facial Nerve : METHODS OF IDENTIFICATION
  METHODS OF PROTECTION
  REPAIR
  REHABILITATION
SUPERFICIAL CONSERVATIVE PAROTIDECTOMY
It is the most common procedure for parotid gland pathology. Surgery is 
performed under ET-GA with/without hypotensive anesthesia to facilitate dissec-
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tion.
Important steps are:
1. Varieties of Incisions have been used over years. Most Common: ‘Lazy S’ 
Preauricular -mastoid-cervical incision.
2. Anterior Skin flap developed just below the parotid fascia upto anterior 
border of parotid gland.
3. Dissection continues in the posterior direction to free the posterior margin 
of parotid.
4) Sternocleido mastoid retracted and GAN divided.
5) Gland gradually mobilized by sharp dissection upto and to the anterior 
aspect of mastoid process identifying posterior belly of digastric.
6) Second avascular plane opened in front of tragus.
7) Facial trunk identified and dissected out along its length.
8) Scissor dissection in the perineural plane above the nerve anteriorly ex-
poses its branches.
9) Facial branches dissected out starting with upper division, freeing the 
superior lobe.
10) Cut facial nerve can be dealt with immediately (see later)
11) In this way, the superficial and its associated tumour are mobilized in a 
superior to inferior dissection.
12. Hemostasis secured
13. Suction drain kept for 24-48 hrs.
14) Wound closed in layers.
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TOTAL CONSERVATIVE PAROTIDECTOMY
It is done for malignant tumours and tumours involving deep lobe.
In addition to the above steps, the deep lobe is also completely excised tak-
ing care to preserve the facial nerve and its branches.
RADIAL  PAROTIDECTOMY
It is performed for patients when there is a clear evidence of high grade 
malignant tumour with extensive VII N infiltration. For example SCC as in our 
case.
This involves removal of all parotid gland tissue and elective sectioning of 
the facial nerve; usually through the main trunk. The surgery invitably removes 
ipsilateral masseter and also requires simultaneous neck dissection.
NECK DISSECTION
Where there is no doubt that neck dissection should be performed for malig-
nant parotid tumours with clinically positive nodes. There is no consensus regard-
ing prophylactive neck dissection. 
Frankenthelin et al M.D. Anderson Cancer Centre has suggested neck dis-
section only in clinically positive nodes where as Perzick et al advocates prophy-
lactive neck dissection for malignant mixed tumour, high grade mucoepidermoid 
carcinoma and adenoid cystic carcinoma.
It is now, generally accepted that if nodes are clinically/radiologically posi-
tive, neck disssection should be done.
SUBMANDIBULAR GLAND EXCISION
For benign tumours, excision of the gland with a cuff of normal tissue is the 
treatment of choice.
For frankly malignant tumours, radical/modified radical neck dissection in-
volving levels I, II & III need to be done, sometimes necessitating the sacrifice 
of nerves.
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Important steps are:
* Performed under endotracheal general anaesthesia
* Incision should be marked at least 3-4 cm below the lower border of 
the mandible to avoid damage to the marginal mandibular branch
* Sharp dissection is performed down to the platysma muscle
* Platysma muscle is incised and the wound margins retracted.
* The underlying investing layer of deep cervical fascia is then di-
vided
* The marginal mandibular branch of the facial nerve normally runs 
on the deep surface of the platysma muscle
* Deepening the incision divides the submandibular gland capsule
* For tumours of the submandibular gland, extracapsular dissection by 
suprahyoid neck dissection is performed
* The superficial lobe of the submandibular gland is first mobilised by 
retracting superiorly with Allis forceps
* Dissection posteriorlty subsequently identifies the facial artery, 
which either enters or passes around the submandibular gland. This artery is di-
vided to facilitate further mobilisationof the gland
* The gland is further dissected by blunt and sharp dissection
* Dissection in the anterior aspect of the superficial lobe ultimately 
identifies the mylohyoid muscle.
* An important landmark in submandibular gland dissection is the 
posterior border of the mylohyoid muscle. Once identified, it can be retracted 
forwards, revealing the deep lobe of the submandibular gland.
* The submandibular gland is now retracted inferiorly, invariably at-
tached to the lingual nerve
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* The gland is now pedicled entirely on the submandibular duct, which 
can be identified and ligated
* The hypoglossal nerves lie deep to the submandibular capsule and 
should not be damaged during intracapsular dissection.
For large tumours, projecting beyond the SM gland are best served by sup-
rahyoid neck dissection carefuly protecting marginal mandibular branch, lingual 
and hypoglossal nerves.
FACIAL NERVE
For any surgeon doing parotid surgery, the Identification & Protec-
tion of facial nerve is the most important step which needs surgical skills. 
The following are some of the tips that aid in identification and preservation of 
facial nerve.
1) ET - GA: Hypotensive anesthesia to facilitate dissection, improve the 
surgical field and to reduce blood loss.
2) Skeletal muscle relaxants avoided to facilitate intraoperative facial nerve 
monitoring like EMG monitoring of facial musculature (or) nerve localistion by 
electrical stimulation
3) Complete familiarity about the surgical anatomy of parotid region, by the 
surgeon.
4) Hemostasis should be absolute throughout the surgery which reduces the 
incidence of nerve injury. Special instruments like Shaw Scalpel and Bipolar scis-
sors with saline irrigation can be used
5) Disisection done either trunk first method (popularised by Martin) or pe-
ripheries first, (Sistrunk, Hobsley, Bailey --> Mandibular branch dissection first; 
Reissner --> dissection starts from Zyg. arch where the branch is constant in posi-
tion).
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6) Landmarks commonly used to identify facial nerve trunk.
a) Inferior position of cartilagenous canal --> Conley’s Pointer
b) Upper border of the posterior belly of digestive muscle.
Once the facial nerve is damaged accidentally or intentionally, the various 
repair and rehabilitation procedure are available. The surgeon must consider pa-
tient’s needs before planning for surgery for Facial Palsy.
FACTORS INFLUENCING FACIAL REANIMATION  PROCEDURE:
1) Status of proximal nerve
2) Status of the distal nerve
3) Status of facial muscles
4) Integrity of the donor nerves
5) Length of time since transection
6) Neural scarring
7) Age
8) Radiation therapy
9) Diabetes
EARLY RECONSTRUCTION:
Usually done during initial surgery.
Frozen section confirmation of negative margins of nerve ends are required
Nerve grafts harvested from
 a) Contralateral greater auricular nerve
 b) Sural nerve)
 c) Median cutaneous nerve of forearm
 d) Cervical branches from C3, C4.
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Proximal and distal ends should be transacted cleanly.
4 epineurial sutures are usually necessary to seal the epineuria around.
Return of function can be expected within 6-9 months.
The axon grows at the rate of 1 mm per day.
DELAYED GRAFTING
When more than 3 days have elapsed after nerve transaction, the technique 
of cable grafting differs, because the distal nerve segment may not be easily 
found.
The surgeon should have pre conceived map to find these distal branches.
The proximal site for cable grafting can be any portion from brain stem dis-
tally, depending on site and nature of facial nerve injury.
PROCEDURES CAN BE DIVIDED INTO 
A. DYMAMIC REANIMATION
a) Interposition nerve grafts
b) Cross over re-innervation procedures
  Hypoglossal
  Ansa - Hypoglossi
  Trigeminal and cross facial
B. STATIC REANIMATION
1) Eye lid procedure
  a) gold weight
  b) spring
  c) lower lid tightening
2) Brow and Forehead lift
3) Correctiono of mid facial deformities
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4) Slings - fascia lata
       Alloplastic sheets
       Malar augmentation
5) Face lift
6) Lower lip wedge resection
RADIOTHERAPY
Adjuvant  RT is given postoperatively in the following settings [Dose: 6000-
7000 cGy in 30 Fractions]
i) Stage III/IV
ii) High grade malignant tumour
iii) Positive resected margins
iv) Recurrent tumours
v) Documented lymph node metastasis
vi) Bone/connective tissue involvement.  PO RT reduces the recurrence ratio 
from 29.6% to 9.1%
Indications for RT as a single modality
a) an unresectable disease.
b) Patient not willing for surgery
c) Comorbid illness precluding surgery
Indications for RT in benign tumours (3000 to 5000 cGy in 17-25 fractions)
a) Recurrernt pleomorphic adenoma
b) Unresectable/incompletely resected tumours.
c) Benign lymphoepithelial lesions.
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COMPLICATIONS OF PAROTID SURGERY
 GENERAL SPECIAL
 - Haemorrhage
 - Haematoma
 - Seroma
 -Wound Infection
 - Flap Necrosis
FREY’S SYNDROME (Gustatory sweating or auriculotemporal nerve syn-
drome)
Results from aberrant regeneration of Autonomic fibres (mediating salivary 
secretion) to cholinergic receptors in skin and sweat glands.
Stimuli that ordinarily promote parotid gland resection results in erythema 
over parotid region and facial sweating
Clinically apparent Frey’s syndrome occurs in 35-60% patients.
Sub-clinical Frey’s can be demonstrated by starch Iodine test.
1. Nerve Injury
 a. Facial Palsy
 b. Frey’s syndrome
 c. Greater auricular nerve in-
jury
 (leading to anasthesia of ear-
lobe)
2. Facial contour defect
3. Salivary fistula
4. Sialocele.
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Treatment
Directed towards blocking the abnormal neural pathway.
a) Topical application of Scopalmino hydrobromide cream (3%)
b) Division or avulsion of auriculotemporal nerve.
c) Intra cranial sectioning of IX nerve
d) Alcohol injection of ganglion
e) Excision of affected skin and grafting the defect.
f) Systemic atropino
g) Facia lata interposition
COMPLICATIONS OF SUBMANDIBULAR GLAND EXCISION
1) Hematoma
2) Wound Infection
3) Nerve Injuries: Marginal mandibular nerve
   ` Hypoglossal nerve
    Lingual Nerve
    Nerve to mylohyoid
    (--> submental skin anesthesia)
COMPLICATIONS OF RADIOTHERAPY
1) Xerostomia
2) Mucoritis
3) Trismus
4) Dental caries
5) Hair loss and skin changes.
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CHEMOTHERAPY
Chemotherapy is given mainly for palliation in inoperable cases and rarely 
as adjuvant therapy.
Main drugs used are cisplatinum, 5- plurouracil, Adriamyani, cyclophospha-
mide, epirulium, Bleomycin etc in various combinations [CAP, PAB regions].
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MATERIALS & METHODS
This study was conducted in Government Stanley Medical College Hospi-
tal, Chennai, from August 2003 to January 2006 for a period of 30 months.
INCLUSION AND EXCLUSION CRITERIA
All patients who came with history of swelling in the salivary gland regions, 
were taken up for the study. A thorough history and clinical examination were 
done for all patients as mentioned in the proforma. In addition to routine inves-
tigations, FNAC was done for all patients. Other and special investigations like 
Incisional Biopsy, CT Scan, Excisional Biopsy were done for appropriate patients 
who needed them.
But a few who absconded while halfway through their treatment plannings 
were excluded from the study. Also few patients whose results came as one other 
than salivary gland neoplasms were also excluded from the study.
Treatment planning was done as appropriate depending on clinical findings 
and investigation results. Patients underwent either surgery alone or radiotherapy 
alone or surgery and adjuvant radiotherapy. Postoperative complications were 
recorded. All patients were followed up for a period ranging from 1 to 7 months.
Results and observations of the study follows:
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RESULTS & OBSERVATIONS
A master chart is designed from the data collected during the study period 
and various epidemiological and other statistical details are analysed, results 
tabulated and graphs/charts given at appropriate places to make easy understand-
ing.
AGE & SEX
Of the 60 patients who underwent our study, there are 29 males and 31 fe-
males showing a very slight female preponderance (sex ratio = 1:1.06).
There were patients ranging from lowest age of 11 years to highest age of 
82 years
The following statistics are calculated:
Mean age = 42.1 years
Median age = 40 years
Age stratification data shows following details:
Age Group No.of patients Percentage
1-10 0
11-20 2 3.3%
21-30 10 16.07%
31-40 22 36.7%
41-50 13 21.7%
51-60 6 10%
61-70 5 8.3%
71-80 1 1.7%
>80 1 1.7%
Total 60 100%
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The  above data shows that 4th decade (31-40 yer) is the most common age 
group for salivary neoplasms (37%) closely followed by 5th decade (41-50 yrs) 
which is 22%
GLANDS
Regarding gland involvement, our study shows that parotid gland is the most 
common salivary gland (82%) involved followed by submandibular gland (15%) 
and minor salivary gland (3%). There was no sublingual gland tumour detected 
in our study.
GLAND M F Total % (n)
PAROTID (n=24) (n=25) 81.6% n(=49)
SUBMANDIBULAR (n+4) (n=5) 15% (n=9)
MINOR SALIVARY GLANDS (n=1) (n=1) 3.3% (n=2)
BENIGN VS MALIGNANT
Out of 60 cases studied, 10 were malignant tumours (16.6%) and 50 were 
benign tumours (83.4%)
Of the 10 malignant tumours (16.6%) 80% (n=8) were in the parotid gland 
and 20% (n=2) of them were in the minor salivary gland. There were no sub-
mandibular malignancies recorded in our study. 
Of the benign tumours, (n=50), 82% of them were in the parotid gland 
(n=41) and 18% (n=9) of them were in the sublingua gland. There were no benign 
tumours in the minor salivary gland; all of them were malignant.
The results are tabulated based on benign and malignant tumours in various 
salivary glands in our study.
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GLANDS AND TUMOURS
Gland Benign Malignant Total
Parotid 41 8 49
Submandibular 9 0 9
Minor Salivary Gland 0 2 2
  Percentage of benign and malignant tumours in various salivary 
glands (our study)
Gland Benign malignant
Parotid 83.7% 16.3%
Submandibular 100% 0%
Minor Salivary gland 0% 100%
Above table stressses the importance that MC Neoplasm of parotid is benign 
and malignant tumour is most common in minor salivary glands.
Further stratification in sex showed the following results:
  
BENIGN MALIGNANT TOTAL GRAND TOTAL
GLAND  M F M F M F
PG 20 21 4 4 24 25 49
SMG 4 5 - - 4 5 9
MSG - - 1 1 1 1 2
TOTAL 24 26 5 5 29 31 60
 In malignant tumours, there is equal sex incidence whereas there is a very 
slight female preponderance for benign tumours.    
 Stratification of pathological types of benign and malignant tumour 
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shows:
TUMOUR MALE FEMALE TOTAL
BENIGN
Pleomorphic Adenoma 19 23 42
Warthin’s tumour 1 0 1
Myoepithelioma 2 1 3
Hemangioma 2 1 3
Benign lympho epithelioma 0 1 1
MALIGNANT
Mucoepidermoid Ca 3 4 7
Malignant mixed tumour 1 0 1
Squamous Cell Ca 1 1 0
Malignang Lymphoepithelioma 1 1 0
The above table shows us certain important facts:
a) Pleomorphic adenoma is the most common benign tumour (42 of 50) ac-
counting for 84%  of benign tumours and is also the most common neoplasm (42 
of 60) accounting 70%
b) Although Warthin’s tumour is considered the second most common be-
nigh tumour, there were only 1 case in our study (2%)
c) There were surprisingly 3 cases of Hemangioma and 3 cases of myoepi-
thelioma each accounting for 6% of benign tumours.
d) Mucoepidermoid carcinoma is the most common cancer accounting for 
70% of malignant tumours. Of the 8 parotid carcinomas, 5 cases were mucoepi-
dermal carcinomas (62.5%).  
100% of the minor salivary gland tumours are mucoepidermal carcinomas 
in our study.
SENSITIVITY AND SPECIFICITY OF FNAC
Regarding the sensitivity and specificity indices, our study shows the fol-
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lowing results:
SENSITIVITY SPECIFICITY
Benign 86.2% 100%
Malignant 71.4% 100%
Overall 83% 100%
The specificity of FNAC is 100% for both benign & malignant conditions. 
but the sensitivity of FNAC is 12% (71% vs 84% for malignancy vs benign) 
higher for diagnosing benign than for malignant conditions. These results are 
comparable with other’s studies as seen in “Discussion” section.
CLINICAL PRESENTATION:
        No. of Cases
Swelling only    -  46
Swelling + Pain    -  11
Swelling + Pain + VII nerve palsy -  2
Swelling + Node    -  1 
The above data shows that asymptomatic swelling is the most common pres-
entation (77%)
- Pain is present in 13 cases (of 60) accounting for 27%
- Preopertive facial nerve involvement is seen in 2 cases - 3.3%
RISK FACTORS 
Of 10 cases of malignant tumours, there were 2 smokers, 2 smokers and 
alcoholics and 1 was an alcoholic and all were male patients.
There were no cases of h/o irradiation before.
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TREATMENT
Regarding treatment modalities, surgery alone was done for 53 cases. Of 
these, superficial conservative parotidectomy is the most comm9on surgery 
done.
Post operative RT was given for 7 cases. 6 cases for malignant parotid tu-
mour and 1 case of recurrent pleomorphic adenoma, where total parotidectomy 
was done.
Wide local excision was done for a minor salivary gland tumour involving 
the floor of the mouth, where preoperative FNAC was inconclusive and incisional 
Bx showed it as squamous carcinoma. Similarly Maxillectomy was done for mi-
nor salivary gland tumour involving maxillary sinus mucosa.
Surgery No.of Patients
Superficial Conservative Parotidectomy 40 (67%)
Total Conservative Parotidectomy 8 (13.3%)
Radial Parotidectomy 2 (3.3%)
WLE 1 (1.7%)
Submandibular Excision 8 (13.3%)
Left Maxillectomy 1 (1.7%)
POST OPERATIVE COMPLICATIONS
Facial Palsy:
Superficial Conservative parotidectomy - 8 of 40
Total conservative /Radical Paraotidectomy - 4of 10
20% of the cases of benign tumours who underwent superficial conservative 
parotidectomy developed facial nerve palsy. Most of them were neuropraxias 
which improved within weeks.
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DISCUSSION
Our study results were compared with various previous studies and were 
analysed. The comparison data showed that most of our study results were com-
parable to previous studies and some interesting facts were also found out.
Studies from Colemann J.J., Jurkiewicz MJ et al were compared with our 
study.
Previous Study Our Study
Benign Parotid tumours 70-80% 83.7%
Pleomorphic adenoma % of benign-
tumours)
80% 84%
MC age V decade IV decade
Correlation between FNAC & HPE 90=-94% >80%
Benign Tumours Stewart C J Izandro R B Malaita J K Our Study
Parotid 63% 74% 70.2% 81.6%
Submandibular 36% 18% 10% 15%
Minor Salivary gland 1% 8% 19% 3.3%
The above comparison study shows that benign tumours are most common 
in parotid gland and malignancy incidence rises as one goes to minor salivary 
gland.
Regarding the mode of presentation, our study’s results compared with 
Conley J et al showed following results:
Symptoms Conley J et al Our study
Swelling Only 58% 79% (46 of 50)
Swelling + Pain 20% 18% (11 of 60)
Swelling + Pain + VII N 12% 3.5% (2 of 60)
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Regarding the incidence of various histopathological varieties of malignant 
parotid tumours (8--> parotid  2--> MSG) our studies were compared with Me-
morial Sloan Kettering Ca Centre (1778 Parotid tumours)
Histology Memorial Sloan Kettering Mayo Clinic Our Study
Mucoepidermoid Ca 32% 27% 50%
Malignant mixed tumour 14% 10% 10%
SCC 16% 6% 10%
From Spiro R, Spiro J, Carcinoma of salivary gland, etition, 2, New york, 
Churchil Livingstone 1984; 645.  The comparison data shows that the most com-
mon malignant salivary neoplasm in all the studies are mucoepidermoid carcino-
mas.
Incidence of Post-operative Facial Palsy
Rappoport et al and Izandro R B have in their studies show an incidence of 
25% and 25.2% facial paresis/palsy after superficial conservative parotidectomy. 
Our study results show that 8 of 40 superficial parotidectomies had facial palsy/
paresis which is 20% and is comparable to other studies.
Most of these facial nerve involvement is neuropraxia rather than Axonot-
mesis or neuronotmesis and most of them improved subsequently. It is due to 
handling of the field during surgery.
Incidence of malignant tumours in various salivary gland
tumours compared
Gland Maynard Palma Suen Our Study
Parotid 20% 45% 30% 16.3%
Salivary gland minor 75% 100% 85% 100%
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The above data sresses the fact that as we go from parotid to-
wards minor salivary gland, the incidence of malignancy increases.
Various parameters of our study were compared with Litter Spiro R, Spiro J 
et al study in malignant salivary tumours.
Litter Spiro R, Spiro J Our Study
Age Incidence 4-6th decade 5th to 7th decade
Sex M Equal sex incidence
Pain 12-24% 50% (5 of 10)
VII N Palsy 8-26% 20% (2 of 10)
Nodes 25% 10% (1 of 10)
FNAC 94% >80%
FNAC - SENSITIVITY & SPECIFITY
FNAC - Sensitivity & Specificity data for malignant tumours and benign 
tumours
Sensitivity Specificity
Benign
Orell 85.5% 99.5%
Candel 95.7% 100%
Our study 86.2% 100%
Malignant
Ferrel C et al 87% 99%
Stewart C J et al 87% 99%
Our STudy 71.4% 100%
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The above results show that specificity for FNAC is high (99 to 100%) for 
both benign and malignant tumours whereas sensitivity is lesser variying from 
71% to 95% in various studies. Provided adequate technique is followed, an 
experienced pathologist can give a FNAC report with sensitivity and specificity 
close to 100%.
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CONCLUSION
From our study, the following conclusions are made:
1) Salivary gland nroplasms are not uncommon neoplasms
2) There is fairly equal sex incidence
3) Among the salivary gland, parotid gland is the commonest salivary gland 
found to be affected by neoplasms (81.6%)
4) Benign tumours especially pleomorphic adenoma is the most common 
neoplasm. It accounts for 84% of benign tumours and 70% of overall tumours
6. In minor salivary gland, all the neoplasms are malignant --> 100% and are 
mucoepidermoid carcinomas.
7) Eventhough, hemangiomas are MC parotid tumour of infancy and chil-
dren, their occurrence and occurrence of other rare diseases like myoepithelioma 
& lymphoepithelioma accounting for 6%, 6% and 3% of benign tumours respec-
tively in our study were rated.
8) The most common presentation is painless slow grouping tumour. Pain is 
present in 27% of cases and facial palsy in 3.3% of cases
9) FNAC is an important simple diagnostic tool, which shows a specificity 
of 100% for diagnosing tumours. The sensitivity is 83% and 71.4% respectively 
for benign and malignant tumours.
10) Superficial conservative parotidectomy is the most common procedure 
done.
11) The incidence of postopeprative facial paresis/palsy after superficial 
parotidectomy is 20%
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PROFORMA
Name
Age
Sex
Occupation
Address
IP No.
HISTORY
Chief Complaint/s 
1. Swelling:  Site where started
   Duration
   Rate of growth
   Sudden change in size of swelling
   Any history of discharge/ulceration
   Any sudden increase in size
2. Pain:  Over the swelling
   Referred pain
   Aggravated by Mastication   
   Duration
   Nature
   Severity
   Radiation
3. Other histories: Salivation
   Nerve involvement
    i) - VII Nerve
    Stasis of food in buccal cavity
    drooling of Saliva
    deviation of angle of mouth
    ocular symptoms
   
    
    ii) - Lingual Nerve
    taste sensation over tongue
    
    iii) Hypoglossal Nerve
    Mastication difficulty
    speech difficulty
   h/o discharge of pus through the duct
   h/o bleeding from ulceration or through duct
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4. Past History: Irradiation
   Previous Surgery
5. Personal history:  Smoking/Alcohol/Tobacco Chewing
6. Family History: 
7. Medical history:  h/o DM/HT/PT
8. Menstrual and
    Obstetric history: For Females
   
GENERAL EXAMINATION
Anaemia
Hydrations
Lymphadenopathy
PR & BP
CLINICAL EXAMINATION
INSPECTION        : Site
(SWELLING)  Lifting of earlobe
    Size
    Shape
    Surface
    Skin over the swelling
    Surroundings
PALPATION:   Warmth
    Tenderness
    Site, Size, Shape and Surface
    Consistency
    Plane
    Mobility/Fixity
    Skin over the swelling
ORAL CAVITY: Bidigital palpation for Submandibular
     and Sublingual glands
    Salivary gland ducts  - Any discharge during
     manipulation 
    Deep lobe involvement  - Bulging of lateral wall,
     Tonsil pushed medially,  Bidigital palpation 
    Others   -  Teeth, tongue etc.
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NERVES:  Facial nerve:
    Loss of wrinkling of forehead
    Weakness of eyelid closure
    Obliteration of nasolabial fold
    Deviation of angle of mouth
    
    Lingual nerve involvement
    Taste Sensation over anterior part of tongue
    Hypoglossal nerve
    Tongue deviation
    
    
CERVICAL 
LYMPHADENOPATHY
EXAMINATION OF OTHER SYSTEMS
RESPIRATORY SYSTEM 
ABDOMEN
CARDIOVASCULAR SYSTEM
CENTRAL NERVOUS SYSTEM
PROVISIONAL DIAGNOSIS:
INVESTIGATIONS
1. ROUTINE INVESTIGATIONS
2. CXR AND ECG 
3. FNAC
4. OTHER INVESTIGATIONS AS NEEDED
   X-Ray local part, CT Scan, Trucut biopsy etc.
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TREATMENT
SURGERY    Supl parotidectomy
      Total conservative parotidectomy
      Total radical parotidectomy
      Resection of submandibular triangle
PEROPERATIVE FINDINGS Type of incision
      Infilteration 
      Deeplobe involvement
      VII nerve 
      
      MACROSCOPIC/CUT SECTION
      FINDINGS 
HISTOPATHOLOGICAL EXAMINATION RESULTS
RADIOTHERAPY 
CHEMOTHERAPY
POSTPOERATIVE    Uneventful
COMPLICATIONS   Wound infection
      Seroma
      Skin flap necrosis
      VII nerve palsy/paresis
      Salivary fistula
      Others
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MASTER CHART Page 1
S. No. Name IP. No. Age Sex Gland SIDE Smoking RT Alcohol Swelling Pain VII 
Nerve
Node Others
1. Balakrishnan 037132 55 M PG L +  + +  
2. Saraswathy 026104 38 F SMG L +
3. Thulasiammal 028979 55 F PG R +
4. Lakshmi 028061 65 F PG R + +
5. Govindammal 031105 23 F SMG L +
6. Lakshmi 029083 49 F PG L +
7. Mani 025655 40 M PG R + + +
8. Meenammal 025191 80 F MSG R + + UG*
9. Mani 026207 53 M PG R +
10. Subramani 022747 65 M PG L + + + + +
11. Muniamma 027474 60 F PG L +
12. Shanthi 034677 41 F PG L + +
13. Munusami 035617 38 M PG R + = +
14. Poongodi 028476 40 F PG L +
15. Md. Shiyaz 028332 45 M PG R + + +
16. Veeramma 025230 40 F PG L +
17. Lakshmi 033147 45 F PG R +
18. Shanmugam 039929 82 M MSG L + + +
19. Ezhilarasan 037891 25 M PG R + + + + ALBI
20. Krishnan 039534 68 M SMG L + +
21. Bagyalakshmi 051450 41 F PG L +
22. Guna 098238 23 M PG R +
23. Poochi 019703 50 M PG R + +
24. Raji 013293 16 M PG L +
25. Janaki 013300 35 F PG R + +
26. Valli 013277 40 F PF L +
27. Perialakshmi 047595 11 F PG R +
28. Revathy 015455 32 F PG L +
29. Panneerselvam 015333 33 M PG R + + +
30 Sathaqathulla 015374 52 M PG R + +
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MASTER CHART Page 2
S. No. Name IP. No. Age Sex Gland SIDE Smoking RT Alcohol Swelling Pain VII 
Nerve
Node Others
31. Mumtaj 039703 35 F PG L +
32. Senthilkumar 002202 28 M PG L +
33. Abdul Razaq 001058 60 M PG R + + + + ULCER
34. Lakshmi 003831 50 F PG R + +
35. Arumugam 003361 35 M PG L + +
36. Shanthiappan 003489 50 M PG R + +
37. Padavattammal 005400 37 F SMG L +
38. Govindammal 007553 40 F PG R +
39. Sandhya 009602 44 F PG R + +
40. Meenakshi 008725 31 F PG L +
41. Kalimuthu 033391 40 M PG R + + +
42. Ganesan 034589 50 M SMG R +
43. Ramakrishnan 008523 65 M PG R +
44. Poongodi 012671 40 F PG R +
45. Jayapal 046519 21 M PG L +
46 Dhanashekar 045568 48 M PG R +
47. Kannan 050778 45 M PG L + =
48. Krishnaswamy 051523 36 M PG R + +
49. Roothu 974009 39 F SMG R +
50. Dhayalan 034301 25 M SMG L +
51. Anjammal 035664 38 F PG L +
52. Sasikala 036873 30 F PG L +
53. Lakshmi 024752 70 F PG L + +
54. Kuttiama 026240 35 F PG R +
55, Marimuthu 026496 24 M PG L + +
56. Parvathy 029357 40 F SMG L +
57. Sambu 030982 46 M SMG R +
58. Geetha 037247 38 F PG R +
59. Maruthamuthu 968169 24 M PG L + +
60. Geetha 371667 22 F PG R +
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MASTER CHART Page 1 (contd)
DIAGNOSIS MANAGEMENT PO BIOPSY PO COMPLICATIONS
S. No. FNAC OTHERS SURG SU + PORT RT UNEVENTFUL SEROMA WOUND INF VII N PALSY OTHERS
1. CAP TCP MEC  H +
2. INC SME PLA +
3. PLA CT SCP PLA + +
4. PLA SCP + MPA +
5. PLA SME PLA +
6. PLA SCP PLA +
7. PLA CT TCP PLA +
8. CA INB WLE MEC +
9. PLA SCP PLA +
10. MEC CT RP + SCC +
11. PLA SCP PLA +
12. MEC CT TCP MEC-L + +
13. PLA SCP PLA +
14. PLA SCP PLA +
15. INC SCP ME +
16. PLA SCP PLA +
17. PLA SCP PLA + +
18. MEC LMX + MEC-H +
19. CA CT TCP MLE + PM-FLAP
20. PLA SME PLA +
21. PLA SCP PLA +
22. INC TCP HEM +
23. WR SCP WR + +
24. PLA SCP PLA +
25. PLA SCP PLA +
26. PLA SCP PLA +
27. PLA SCP PLA +
28. WR SCP PLA +
29. PLA SCP PLA +
30 PLA SCP PLA +
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MASTER CHART Page 2 (contd)
DIAGNOSIS MANAGEMENT PO BIOPSY PO COMPLICATIONS
S. No. FNAC OTHERS SURG SU + PORT RT UNEVENTFUL SEROMA WOUND INF VII N PALSY OTHERS
31. PLA SCP PLA +
32. NODE SCP PLA +
33. MEC RP + MEC-H +
34. INC CT TCP + MEC-L + +
35. PLA SCP PLA +
36. PLA SCP PLA +
37. INC SME ME +
38. PLA SCP PLA +
39. MEC CT TCP + MEC-I +
40. PLA SCP PLA +
41. PLA SCP PLA +
42. PLA SME PLA +
43. PLA SCP PLA +
44. PLA SCP ME +
45. INC TCP HEM +
46 PLA SCP PLA +
47. PLA SCP PLA +
48. PLA SCP PLA +
49. PLA SME PLA +
50. PLA SME PLA +
51. BLE SCP BLE +
52. PLA SCP PLA +
53. PLA SCP PLA +
54. HEM SCP HEM +
55. PLA SCP PLA +
56. PLA SCP PLA +
57. PLA SME PLA +
58. PLA SCP PLA +
59. PLA SCP PLA +
60. PLA SCP PLA +
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LIST OF ABBREVIATIONS USED IN MASTER CHART:
PLA - PLEOMORPHIC ADENOMA
MEC - MUCO EPIDERMOID CARCINOMA (H = HIGH GRADE, L = LOW GRADE, I = INTERMEDITE GRADE)
INC - INCONCLUSIVE
BLE - BENIGN LYMPHO EPITHELIOMA
HEM - HEMANGIOMA
CT - CT SCAN
SCP - SUPERFICIAL CONSERVATIVE PAROTIDECTOMY
TCP - TOTAL CONSERVATIVE PAROTIDECTOMY
SME - SUBMANDIBULAR EXCISION
LMX - LEFT MAXILLECTOMY
WLE - WIDE LOCAL EXCISION
RP - RADICAL PAROTIDECTOMY
MLE - MALIGNANT LYMPHO EPITHELIOMA
WR - WARTHIN’S TUMOUR
ME - MYOEPITHELIOMA
PG - PAROTID GLAND
SMG - SUBMANDIBULAR GLAND
MSG - MINOR SALIVARY GLAND
PORT - POST OPERATIVE RADIO THERAPY
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